Jubilant Life Sciences, a global Pharmaceutical and Life Sciences company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients registered 22 percent growth for the ninth months ended December 2012 with income from operations was at Rs 3,769 crore. This was led by volume increase of 18 percent. The Profit before exceptional items, tax and minority interest in the period was Rs 455 crore, up 34 percent Year on Year (YoY). The Reported Profit after tax was at Rs 184 crore after adjusting exceptional items of Rs 132 crore. The Normalised PAT stood at Rs 316 crore, up 13 percent from same period last year.
Commenting on the company's performance, Mr Shyam S Bhartia, Chairman and Managing Director and Mr Hari S Bhartia, Co-Chairman and Managing Director, Jubilant Life Sciences said,"During the nine months period, the company delivered a strong revenue growth of 22 percent with 26 percent EBITDA growth, driven by pharma segment top line growth of 26 percent and business EBITDA growth of 46 percent. Our strategy of enhancing presence in identified international markets is delivering results with 28 percent growth and high 73 percent contribution to revenue mix. We believe this momentum is sustainable due to strong product pipeline and order book position along with leveraging benefits from vertical integration."
Pharmaceuticals segment review
The Pharmaceutical segment comprises of APIs, Generics, Speciality Pharma, CMO, DDDS and Healthcare. In nine months FY2013, the Income from operations of the segment stood at Rs 1,956 crore, up 26 percent YoY and contributing 52 percent to the revenue mix. The segment EBITDA was 46 percent higher at Rs 575 crore, up from Rs 394 crore last year. The corresponding EBITDA margins stood at 29.4 percent compared to 25.3 percent in the previous period.
Strong volume growth in Generics and Specialty Pharma continued to drive performance for the segment. While APIs witnessed flattish YoY growth in Q3'FY13, CMO services witnessed some deferment of sales which are expected to be realised in the current quarter.